Jonathan Milner, co-founder and currently Deputy Chairman of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK healthcare and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on AIM.
Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath University. From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the laboratory of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Kouzarides.
Jonathan is currently Chairman of Axol Bioscience, Camallergy Limited, Definigen Limited and PhoreMost Limited and a non-executive director of Horizon Discovery, Syndicate Room Limited, Repositive Limited, Elpis Biomedical Limited, Shift Biosciencs Limited and HealX Limited. He also sits on the advisory board of Desktop Genetics Ltd.